Novo Nordisk’s Victoza secures FDA paediatric approval for type 2 diabetes
Victoza was approved by the regulator for the treatment of type 2 diabetes in adult patients in 2010. It is now the first non-insulin drug to be approved
The Calquence, obinutuzumab combination registered a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) during the trial, which was the primary endpoint. This was in comparison to the
The venetoclax, obinutuzumab combination met the primary endpoint of the late-stage trial called CLL14, which was investigator-assessed progression-free survival (PFS). The combination therapy, which was administered for a
The Kisqali combination therapy, which was evaluated in both pre- and perimenopausal women in the late-stage trial called MONALEESA-7, delivered statistically significant overall survival (OS) results in comparison